- Title
- Dyslipidemia Is Associated With Worse Asthma Clinical Outcomes: A Prospective Cohort Study
- Creator
- Liu, Lei; Liu, Ying; Liu, Dan; Wang, Gang; Wood, Lisa G.; Zhang, Xin; Yuan, Yu Lai; Chen, Zhi Hong; Chen-Yu Hsu, Alan; Oliver, Brian G.; Xie, Min; Qin, Ling; Li, Wei Min
- Relation
- Journal of Allergy and Clinical Immunology: In Practice Vol. 11, Issue 3, p. 863-872.E8
- Publisher Link
- http://dx.doi.org/10.1016/j.jaip.2022.11.037
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2022
- Description
- Background: Dyslipidemia has been widely documented to be associated with cardiovascular disease, and recent studies have found an association with asthma prevalence. However, longitudinal studies investigating the relationships between dyslipidemia, asthma phenotypes, and future asthma exacerbations (AEs) are lacking. OBJECTIVE: To investigate the relationships between dyslipidemia, asthma phenotypes, and AEs. Methods: This study used an observational cohort study design with a 12-month follow-up. All subjects underwent serum lipid measurement, and they were then classified into 2 groups: the normal-lipidemia group and the dyslipidemia group. Demographic and clinical information and details regarding pulmonary function and asthma phenotypes at baseline were collected. All patients were followed up regularly to assess AEs. Associations of dyslipidemia with airway obstruction and asthma phenotypes were assessed at baseline, whereas dyslipidemia and AEs were assessed longitudinally. Results: A total of 477 patients with asthma were consecutively enrolled in this study. At baseline, the dyslipidemia group (n = 218) had a higher proportion of uncontrolled asthma, defined by the 6-item Asthma Control Questionnaire score (≥1.5). Furthermore, dyslipidemia was associated with severe asthma, nonallergic asthma, asthma with fixed airflow limitation, and older adult asthma phenotypes at baseline. In addition, dyslipidemia was associated with increased frequencies of severe AEs and moderate to severe AEs during the 12-month follow-up. In sensitivity analyses, after excluding the patients who were receiving statins, results did not differ significantly from those of the main analysis. Conclusions: We identified the clinical relevance of dyslipidemia, which is associated with specific asthma phenotypes and increased AEs, independent of other components of metabolic syndrome. These findings highlight the importance of considering dyslipidemia as an "extrapulmonary trait" in asthma management.
- Subject
- dyslipidemia; asthma phenotypes; exacerbations; cardiovascular disease; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1481420
- Identifier
- uon:50719
- Identifier
- ISSN:2213-2198
- Language
- eng
- Reviewed
- Hits: 789
- Visitors: 788
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|